Single Incision Versus Three Port Laparoscopic Cholecystectomy

Overview

Laparoscopic cholecystectomy (LC) became the standard treatment for symptomatic gallbladder disease. Single incision laparoscopic surgery (SILS) was developed with the aim of reducing the invasiveness of conventional laparoscopy. The aim of this study was to compare the clinical outcome of single-incision laparoscopic cholecystectomy (SILC) with three port laparoscopic cholecystectomy (TPLC).

Full Title of Study: “Single Incision Versus Three Port Laparoscopic Cholecystectomy in Symptomatic Gallstones: A Prospective Randomized Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 2016

Detailed Description

From February 2014 to September 2016, patients with symptomatic cholecystolithiasis at two university hospitals (Sohag University and Qena University hospitals) were enrolled in this study. The number of patients needed was calculated. Considering a power of 80% and reliability of 0.05, the investigator found that 76 patients should be present in each group. The study was started with 275 patients for the possible loss of patients and data during the study. Eligible patients (206 patients) were randomly divided equally into two groups (Group 1; SILC, Group 2; TPLC) according to a computer-generated random numbers. Of 103 patients allocated to intervention in each group, 14 patients were excluded from SILC group and 5 patients from TPLC group, and the remaining 89 & 98 patients in SILC & TPLC group respectively were included in the study. Routine investigations and surgical fitness were done in all cases. Patient demographics, BMI, ASA score, indication for cholecystectomy, operative time, estimated blood loss, success and conversion rate, postoperative pain score, postoperative analgesia requirement, morbidity and mortality, length of hospital stay, and patient cosmetic satisfaction were recorded. A fixed analgesia protocol with intravenous non-narcotic (ketorolac tromethamine 30 mg) was used twice daily. An opioid (pethidine Hcl 50 mg) was added when the pain cannot be tolerable. Postoperative pain was evaluated according to a visual analogue scale (VAS) from 0 (no pain) to 10 (maximum pain) on the postoperative sixth hour (VAS-6H) and on postoperative day one (VAS-24H). Patient cosmetic satisfaction was recorded at one month follow-up visit on a scale from 1 (worst) to 10 (best). Patients were shown the same photograph of a right sub-costal (Kocher) incision which was rated 0 on the cosmetic scale and were asked to rate their satisfaction based on the previous observation. The study protocol was approved by the local ethical committee. Also, a written informed consent was obtained from all patients' prior recruitment to study.

Interventions

  • Device: Single incision laparoscopic cholecystectomy
    • Laparoscopic cholecystectomy with single port device
  • Device: Three port laparoscopic cholecystectomy
    • Laparoscopic cholecystectomy with three port

Arms, Groups and Cohorts

  • Active Comparator: Single incision LC
    • Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
  • Sham Comparator: Three port LC
    • Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars

Clinical Trial Outcome Measures

Primary Measures

  • postoperative pain, visual analogue scale (VAS)
    • Time Frame: at 6 hours
    • Postoperative pain was evaluated according to a visual analogue scale (VAS) from 0 (no pain) to 10 (maximum pain) on the postoperative hour six (VAS-6H).
  • postoperative pain, visual analogue scale (VAS)
    • Time Frame: at 24 hours
    • Postoperative pain was evaluated according to a visual analogue scale (VAS) from 0 (no pain) to 10 (maximum pain) on the postoperative day one (VAS-24H).

Secondary Measures

  • operative duration
    • Time Frame: From introduction of first trocar to the recovery of patient, up to 10 hours
  • post operative opioid requirements (questioner)
    • Time Frame: 24 hours
  • lenght of hospital stay
    • Time Frame: from recovery of anaesthesia to discharge of patient, up to 4 days
  • cosmetic satisfactions (aesthetic scale)
    • Time Frame: one month
    • Patient aesthetic satisfaction was recorded at one month follow-up visit on a scale from 1 (worst) to 10 (best). Patients were shown the same photograph of a right sub-costal (Kocher) incision which was rated 0 on the aesthetic scale and were asked to rate their satisfaction based on the previous observation.

Participating in This Clinical Trial

Inclusion Criteria

1. preoperative diagnosis of symptomatic gallstones 2. age from 20 to 60 years, 3. American Society of Anesthesiologists (ASA) grade I, II or III, 4. agreement to complete the study requirement. Exclusion Criteria:

1. patients with contraindication to laparoscopy, 2. suspected Mirizzi syndrome, 3. choledocholithiasis, 4. hepatobiliary malignancy, 5. previous upper abdominal surgery, 6. previous mesh repair of an umbilical hernia, 7. long-term anticoagulant treatment, 8. pregnant female 9. stone more than 2 cm in preoperative ultrasonography.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • South Valley University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mohammed Ahmed Omar, Lecturer of GIT surgery and laparoendoscopy – South Valley University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.